Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.63 Insider Own47.40% Shs Outstand48.26M Perf Week0.00%
Market Cap64.19M Forward P/E- EPS next Y-1.30 Insider Trans0.00% Shs Float25.38M Perf Month-14.47%
Income-68.17M PEG- EPS next Q-0.40 Inst Own38.32% Short Float4.93% Perf Quarter-12.50%
Sales9.16M P/S7.01 EPS this Y8.14% Inst Trans-1.22% Short Ratio2.92 Perf Half Y-64.91%
Book/sh3.52 P/B0.38 EPS next Y12.92% ROA-37.42% Short Interest1.25M Perf Year-73.29%
Cash/sh3.64 P/C0.37 EPS next 5Y- ROE-43.04% 52W Range1.02 - 7.64 Perf YTD-32.49%
Dividend Est.- P/FCF- EPS past 5Y-7.46% ROI-38.53% 52W High-82.59% Beta0.36
Dividend TTM- Quick Ratio12.58 Sales past 5Y280.42% Gross Margin81.43% 52W Low30.39% ATR (14)0.11
Dividend Ex-Date- Current Ratio12.58 EPS Y/Y TTM13.98% Oper. Margin-823.23% RSI (14)47.11 Volatility7.56% 7.88%
Employees43 Debt/Eq0.06 Sales Y/Y TTM-41.34% Profit Margin-744.09% Recom1.00 Target Price9.50
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q-4.86% Payout- Rel Volume0.78 Prev Close1.26
Sales Surprise-73.02% EPS Surprise1.49% Sales Q/Q-87.91% EarningsMar 12 BMO Avg Volume428.38K Price1.33
SMA20-1.70% SMA50-5.49% SMA200-55.06% Trades Volume333,927 Change5.56%
Date Action Analyst Rating Change Price Target Change
Sep-22-23Initiated Wedbush Outperform $11
May-04-23Resumed H.C. Wainwright Buy $18
Dec-23-21Initiated H.C. Wainwright Buy $25
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Apr-10-24 08:00AM
Mar-12-24 08:00AM
Feb-27-24 08:00AM
Feb-21-24 04:15PM
Feb-14-24 09:35AM
09:35AM Loading…
Jan-24-24 09:35AM
Jan-19-24 06:25AM
Jan-18-24 04:05PM
Nov-09-23 07:00AM
Nov-07-23 08:00AM
Sep-27-23 09:01AM
Sep-05-23 08:00AM
Aug-12-23 08:07AM
Aug-10-23 09:30AM
06:08AM Loading…
Aug-08-23 08:24AM
Aug-07-23 07:00AM
Jun-20-23 08:50AM
Jun-05-23 02:59PM
Jun-02-23 08:50AM
May-24-23 08:00AM
May-16-23 08:29AM
May-15-23 09:05AM
May-10-23 05:35PM
May-08-23 12:07PM
09:00PM Loading…
May-04-23 09:00PM
May-03-23 08:50AM
May-02-23 09:29PM
Apr-20-23 08:00AM
Apr-17-23 09:00AM
Mar-14-23 08:15AM
Mar-07-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 07:13AM
Feb-28-23 08:00AM
Dec-22-22 07:13AM
Dec-19-22 04:30PM
Nov-28-22 12:11PM
Nov-22-22 07:30AM
Nov-11-22 10:05AM
Nov-10-22 09:00AM
Nov-07-22 09:25AM
Oct-26-22 07:30AM
Oct-18-22 07:30AM
Oct-05-22 08:05AM
Sep-22-22 06:25AM
Sep-06-22 07:30AM
Aug-12-22 07:41AM
Aug-11-22 08:45AM
Jul-14-22 10:43AM
Jul-06-22 07:00AM
Jun-22-22 07:00AM
Jun-14-22 09:13AM
May-18-22 07:00AM
May-15-22 08:41AM
May-13-22 08:28AM
May-12-22 08:35AM
May-11-22 08:44AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-13-22 07:00AM
Apr-12-22 02:01PM
Mar-28-22 05:37PM
Mar-17-22 07:00AM
Mar-07-22 04:30PM
Mar-01-22 07:00AM
Feb-03-22 04:35PM
Jan-26-22 07:00AM
Dec-24-21 12:38AM
Dec-23-21 06:05AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-08-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-04-21 07:00AM
Nov-02-21 08:00AM
Oct-07-21 09:00AM
Oct-01-21 08:15AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-08-21 07:00AM
Jun-26-21 05:18AM
May-26-21 07:00AM
May-13-21 07:00AM
Apr-15-21 07:00AM
Mar-30-21 04:05PM
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.